Shanghai University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shanghai China (1922)

Organization Overview

First Clinical Trial
2007
NCT00548223
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Department of Emergency and Critical Care Medicine, Zhoupu Hospital affiliated with Shanghai University of Medicine and Health Sciences, Shanghai 201318, PR China | Hongpeng Li | Longhua Hospital | Longhua Hospital Affiliated to Shanghai University | Longhua Hospital Of Baoan District, Shenzhen | Shanghai Mengchao Cancer Hospital | Shanghai University | Zhoupu Hospital, Pudong New Area, Shanghai, China

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma of Lung (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 2)

Brain Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cerebral Infarction (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2)

Cognitive Dysfunction (Phase 2)

Diarrhea (Phase 4)

Hepatitis (Phase 4)

Hepatitis B (Phase 4)

Hypertension (Phase 4)

Hypertension, Portal (Phase 4)

Ischemia (Phase 4)

Lung Neoplasms (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Musculoskeletal Diseases (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pelvic Infection (Phase 4)

Pelvic Inflammatory Disease (Phase 4)

Pneumonia (Phase 2)

Radiculopathy (Phase 4)

Recurrence (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial APIs: 49